The Medicare Payment Advisory Commission is rethinking how Medicare Part B should manage high-cost drugs approved through the US Food and Drug Administration’s accelerated approval pathway, informed by the Centers for Medicare and Medicaid Services’ recent experience with imposing coverage with evidence development (CED) requirements on such drugs.
MedPAC recommended in its June report that CMS should combine CED with Medicare payment caps to lower costs for certain...







